PF-06826647

DRUG3 trials

Sponsors

Pfizer

Conditions

Acne InversaHealthyPsoriasis

Phase 1

A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female Participants

CompletedNCT04134715

Start: 2019-10-23End: 2020-01-09Updated: 2020-02-05

Phase 2

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

CompletedNCT03895372

PfizerPsoriasis

Start: 2019-06-27End: 2020-11-26Updated: 2021-08-27

A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

CompletedNCT04092452

PfizerAcne Inversa

Start: 2019-12-02End: 2022-01-10Updated: 2023-06-15

Related Papers

Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (<scp>IHS4</scp>): A post hoc analysis of the <scp>SUNSHINE</scp> and <scp>SUNRISE</scp> trials

Journal of the European Academy of Dermatology and Venereology2024-10-196 citations

Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa

NEJM Evidence2024-02-0928 citations

Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study.

2022-04-0638 citations